Tumor-associated mitochondrial antigen peptide–MHC complex (TAMA-MHC)

Tumor-associated mitochondrial antigen (TAMA) peptide–MHC complexes are a class of therapeutic targets consisting of peptides derived from mitochondrial proteins presented on the surface of cancer cells by Major Histocompatibility Complex (MHC) molecules (biorxiv.org, 2025; nih.gov, 2022). These peptides often originate from somatic mutations in mitochondrial DNA (mtDNA) or from the aberrant processing and overexpression of mitochondrial proteins, creating neoantigens that are absent in normal tissues (nih.gov, 2022; frontiersin.org, 2020). Recognition of these complexes by T-cell receptors (TCRs) on CD8+ T cells triggers a potent cytotoxic immune response against the tumor (biorxiv.org, 2025). Therapeutic strategies targeting TAMAs include personalized cancer vaccines, TCR-engineered T cells (TCR-T), and TCR-like antibodies, which aim to exploit the unique genetic and metabolic profile of tumor mitochondria (biorxiv.org, 2025; aacrjournals.org, 2023). These approaches are particularly promising for tumors with low nuclear mutational burdens, as they expand the pool of targetable neoantigens and can be combined with immune checkpoint inhibitors to enhance clinical efficacy (biorxiv.org, 2025; mdpi.com, 2024). However, challenges such as potential off-target toxicity due to the conservation of mitochondrial proteins and the downregulation of MHC molecules by tumors must be addressed (frontiersin.org, 2020; nih.gov, 2000).

Other names

Tumor-associated mitochondrial antigensTAMAsMitochondrial-derived neoantigensmt-pMHCMitochondrial peptide-MHC complexMitochondrial-derived antigens

Induction of antigen-specific T-cell mediated cytotoxicity and enhancement of the adaptive immune response against tumor cells presenting mitochondrial-derived neoepitopes.